A Phase 2 interventional study of Cyclophosphamide 50mg and Abatacept in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing cyclophosphamide in Anemia, Sickle Cell — 3 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Anemia, Sickle Cell.
Among the 19 studies testing cyclophosphamide in Anemia, Sickle Cell, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 11 in phase 2, and was the 19th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →3 of the 19 studies testing cyclophosphamide in Anemia, Sickle Cell are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 2–50
University of Illinois at Chicago · Sites in United States
Ages 16–60
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: Up to 22 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 1
First in 1992; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 23 across the 19 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital: 15 open now, 17 under way, none of them phase 3. Of 27 finished, 8 (30%) have results posted.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 11th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 44th registered.
St. Jude Children's Research Hospital’s Anemia, Sickle Cell studies by the year they started, since 1992.
1 of the studies testing cyclophosphamide in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05736419Memorial Sloan Kettering Cancer CenterA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | 2027-02-09 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing cyclophosphamide in Anemia, Sickle Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among St. Jude Children's Research Hospital’s 45 in Anemia, Sickle Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD.
Primary Objective:
- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD.
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Transplant Recipient
Donor
Exclusion Criteria:
Transplant Recipient
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cyclophosphamide 50mg · Drug: Abatacept · Drug: Alemtuzumab · Drug: Hydroxyurea · Drug: Thiotepa · Drug: Filgrastim · Drug: Sirolimus · Drug: Azathioprine · Radiation: TBI · Procedure: Hematopoietic Progenitor Cell Infusion
IV
IV
IV
IV
IV
IV
IV
IV
Radiaiton therapy
Hematopoietic Progenitor Cell Infusion
GVHD-free and rejection free survival (GRFS)
GRFS is defined as the time interval from transplant (graft infusion) until the first of grade III-IV acute GVHD, moderate or severe chronic GVHD, primary or secondary graft failure requiring second definitive therapy, and death occurs. GRFS will be calculated at 1-year, and 3-year post-transplant and reported as a percentage of the enrolled patients.
Time frame: Up to 3 years after HCT
Overall survival (OS)
Event for OS will include death due to any cause. OS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients.
Time frame: Up to 3 years after HCT
Disease-free survival (DFS)
Events for DFS will include death due to any cause and recurrence of SCD symptoms or graft failure after HCT. DFS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients.
Time frame: Up to 3 years after HCT
Incidence and severity of acute and chronic GVHD
Incidence of acute GVHD will be evaluated and reported at 1 month and, 3 months, and 6 months after HCT as a percentage of the enrolled patients. Incidence of chronic GVHD will be evaluated and reported at 6 months, 1 year and 3 years after HCT as a percentage of the enrolled patients
Time frame: Up to 3 years after HCT
Neutrophil and platelet engraftment
The time to neutrophil and platelet engraftment will be reported in aggregate for all the participants using summary statistics.
Time frame: Up to 6 months after HCT
Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available at the time of article publication.
Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2034, 96 months after the start.
Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 96 months is above that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Abatacept · Alemtuzumab · Hydroxyurea · Thiotepa · Filgrastim · Sirolimus · Azathioprine
St. Jude Children's Research Hospital →